 Colistin
"Colistin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.
| Descriptor ID |
D003091
|
| MeSH Number(s) |
D04.345.566.780.110 D10.477.750.110 D12.644.050.600.110 D12.644.641.780.110 D12.776.543.695.054.600.110
|
| Concept/Terms |
Colistin- Colistin
- Colisticin
- Polymyxin E
- Colimycin
|
Below are MeSH descriptors whose meaning is more general than "Colistin".
Below are MeSH descriptors whose meaning is more specific than "Colistin".
This graph shows the total number of publications written about "Colistin" by people in this website by year, and whether "Colistin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 | | 2007 | 1 | 0 | 1 | | 2011 | 1 | 1 | 2 | | 2013 | 1 | 0 | 1 | | 2014 | 3 | 0 | 3 | | 2016 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Colistin" by people in Profiles.
-
Phe K, Shields RK, Tverdek FP, Aitken SL, Guervil DJ, Lam WM, Musgrove RJ, Luce AM, Tam VH. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study. J Antimicrob Chemother. 2016 Dec; 71(12):3585-3587.
-
Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2015 Feb; 15(2):225-34.
-
Phe K, Johnson ML, Palmer HR, Tam VH. Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin. Antimicrob Agents Chemother. 2014 Nov; 58(11):6946-8.
-
Phe K, Lee Y, McDaneld PM, Prasad N, Yin T, Figueroa DA, Musick WL, Cottreau JM, Hu M, Tam VH. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014 May; 58(5):2740-6.
-
Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis. 2014 Jan; 58(1):139-41.
-
Santimaleeworagun W, Wongpoowarak P, Chayakul P, Pattharachayakul S, Tansakul P, Garey KW. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Southeast Asian J Trop Med Public Health. 2011 Jul; 42(4):890-900.
-
Kwa AL, Falagas ME, Michalopoulos A, Tam VH. Benefits of aerosolized colistin for ventilator-associated pneumonia: absence of proof versus proof of absence? Clin Infect Dis. 2011 May; 52(10):1278-9; author reply 1279-80.
-
Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther. 2007 Oct; 5(5):811-21.
-
Kwa AL, Loh C, Low JG, Kurup A, Tam VH. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis. 2005 Sep 01; 41(5):754-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|